The global anti ageing drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Anti-aging drugs are a combination of advanced biotechnology and clinically proven preventative medicines used to prevent and treat age-related disorders and diseases. The increasing demand for anti-stretch mark products as a result of the rising incidence of obesity, particularly among the elderly, and the increased focus of major companies on the launch of advanced devices and products for the treatment of stretch marks are expected to drive the segment’s growth. For instance, in 2020, anti-aging drugs, such as Rapamycin and Doxycycline, have been suggested for the treatment of COVID-19 infection, according to a research article published in Aging, as these drugs can inhibit protein synthesis by blocking viral replication.
A full report of Wooden Decking Market is available at:https://orionmarketreports.com/global-anti-ageing-drugs-market/92802/
The global anti-aging drugs market is witnessing an increase in biotechnology companies’ research activities aimed at developing drugs to extend normal human lifespan. For instance, in 2021, Elevian, Inc., conducted research on a protein known as growth differentiation factor 11. (GDF11). When given to old mice, this protein was discovered to improve brain function, exercise ability, and speed up the muscle repair process.
Many manufacturers have expressed interest in recent discoveries indicating the use of pharmacology to delay and possibly improve the ageing process. However, such discoveries should help to extend the lives of older people while also maintaining their quality of life. The introduction of such anti-aging drugs will result in a reduction of the socioeconomic burden, particularly in developed countries. As a result, research and development of anti-aging drugs is at the forefront in developed countries such as North America and Europe.
Furthermore, anti-wrinkle products, on the other hand, are expected to grow at a significant rate, owing to increased awareness of product availability and an ageing population. For instance, in November 2020, SofWave Medical obtained CE Mark for its next-generation Sofwave system, which was approved for use in the European Union for the treatment of fine lines and wrinkles. As a result of all of the aforementioned factors, the market is expected to expand significantly during the forecast period.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Type
- By Treatment
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape- Novartis AG, BioTime Inc., ARK Skincare, Elysium Health Inc., Estee Lauder Inc., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Anti Ageing Drugs Market Report by Segment
By Type
- Anti-wrinkle Products
- Anti-stretch Mark Products
- Hair Color Products
- Other Products
By Treatment
- Hair Restoration
- Anti-Pigmentation
- Adult Acne Therapy
- Breast Augmentation
- Liposuction
- Chemical Peel
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
